November 17, 2011 — Westside Medical Imaging of Beverly Hills announces the availability of high resolution magnetic resonance imaging (MRI) with a 3 Tesla magnet to monitor the effects of cholesterol drugs on atherosclerosis.

November 18, 2011 – An analysis of the TRITON-TIMI 38 trial presented today in an oral session at the American Heart Association (AHA) Scientific Sessions meeting examined the effect of Effient (prasugrel) on cardiovascular (CV) events (CV death, myocardial infarction [MI] and stroke) compared to clopidogrel relative to the timing of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with ST-segment elevation myocardial infarction (STEMI).

 

November 18, 2011 – CorMatrix Cardiovascular Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the company full investigational device exemption (IDE) approval for its ongoing multi-center, prospective, randomized clinical trial aiming to demonstrate the safety and efficacy of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation following isolated primary coronary artery bypass graft (CABG) surgery. CorMatrix Cardiovascular is a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue.

November 18, 2011 – Boston Scientific’s Watchman left atrial appendage (LAA) closure device has been implanted in the first patients in Latin America. The device is designed for use in patients in atrial fibrillation who are at risk for stroke and are eligible for long-term oral anticoagulation therapy such as warfarin. Watchman is intended to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. The first patient implants were performed by Bernardo Caicedo, M.D., interventional cardiologist, at Angiografia de Occidente in Cali, Colombia.

November 18, 2011 – W. L. Gore & Associates Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the Conformable Gore Tag thoracic endoprosthesis as a minimally invasive treatment for patients suffering from thoracic aortic aneurysms (TAAs). The announcement came at the VEITH Symposium 2011 Conference in New York. The device is the only FDA-approved polytetrafluoroethylene (PTFE) thoracic endoprosthesis designed for endovascular repair of the descending thoracic aorta that offers conformability and ease of use, while accommodating tapered anatomy and resisting compression. The broad oversizing window for the device ranges from six to 33 percent, allowing physicians to choose the appropriate oversizing for the patient anatomy.

November 18, 2011 – The first comprehensive report to review timing of treatment for patients with blockages in more than one coronary artery recommends a flexible approach that meets individual patient’s needs. The report was issued today by the Society for Cardiovascular Angiography and Interventions (SCAI) and is published online in Catheterization and Cardiovascular Interventions.

November 18, 2011 —The Berlin Heart Group announced today that clinical trial data were presented this morning at the “Scientific Sessions 2011” annual meeting of the American Heart Association (AHA). These data showed that, in a clinical trial of children with severe heart failure who were waiting for a heart transplant, 90 percent of patients in the primary cohort of the study were successfully bridged to a heart transplant using Berlin Heart Excor pediatric ventricular assist device (VAD).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now